101. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement
- Author
-
Timothy S. Fenske, Victor Lewis, Brian J. Bolwell, Philip A. Rowlings, Hillard M. Lazarus, Julie M. Vose, Mei-Jie Zhang, Silvia Montoto, David A. Rizzieri, Reinhold Munker, Richard T. Maziarz, Ginna G. Laport, Dipnarine Maharaj, Robert Peter Gale, Wael Saber, Brandon Hayes-Lattin, John Gibson, Hanna Jean Khoury, Prakash Satwani, Luis Isola, Leona Holmberg, Cesar O. Freytes, Edmund K. Waller, Parameswaran Hari, Andy I. Chen, David J. Inwards, Gordon L. Phillips, David G. Maloney, and Zhiwei Wang
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Article ,Extranodal Disease ,Central Nervous System Neoplasms ,Young Adult ,International Prognostic Index ,immune system diseases ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Autologous transplantation ,Humans ,Young adult ,Karnofsky Performance Status ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Lymphoma, Non-Hodgkin ,Age Factors ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,Lymphoma ,Treatment Outcome ,Immunology ,Female ,business - Abstract
Pre-existing central nervous system (CNS) involvement may influence referral for autologous haematopoietic cell transplantation (AHCT) for patients with non-Hodgkin lymphoma (NHL). The outcomes of 151 adult patients with NHL with prior secondary CNS involvement (CNS(+) ) receiving an AHCT were compared to 4688 patients without prior CNS lymphoma (CNS(-) ). There were significant baseline differences between the cohorts. CNS(+) patients were more likely to be younger, have lower performance scores, higher age-adjusted international prognostic index scores, more advanced disease stage at diagnosis, more aggressive histology, more sites of extranodal disease, and a shorter interval between diagnosis and AHCT. However, no statistically significant differences were identified between the two groups by analysis of progression-free survival (PFS) and overall survival (OS) at 5 years. A matched pair comparison of the CNS(+) group with a subset of CNS(-) patients matched on propensity score also showed no differences in outcomes. Patients with active CNS lymphoma at the time of AHCT (n = 55) had a higher relapse rate and diminished PFS and OS compared with patients whose CNS lymphoma was in remission (n = 96) at the time of AHCT. CNS(+) patients can achieve excellent long-term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis.
- Published
- 2013